Bookmark
Forward
QuickView for pentoxifylline (compound)
PubChem
| Name: | Pentoxifylline |
|---|---|
| PubChem Compound ID: | 4740 |
| Description: | A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. |
| Molecular formula: | C13H18N4O3 |
| Molecular weight: | 278.307 g/mol |
| Synonyms: |
3,7-Dimethyl-1-(5-oxohexyl)xantine; Trental (TN); Pentoxifilina [INN-Spanish]; 3,7-Dimethyl-1-(5-oxo-hexyl)-3,7-dihydro-purine-2,6-dione; AIDS-001608; KBio2_001924; Pentoxyphyllin; EHT 0201; 1-(5-Oxohexyl)-3,7-dimethylxanthine; Pentoxiphylline.
show more » |
DrugBank
Identification
| Name: | Pentoxifylline |
|---|---|
| Name (isomeric): | DB00806 |
| Drug Type: | small molecule |
| Description: | A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. |
| Synonyms: |
EHT0201
|
| Brand: | Pentoxyphylline, Pentoxiphyllium, Rentylin, Pentoxifyllin, Pentoxyfylline, Torental, Azupentat, Durapental, Vazofirin, Oxpentifylline, Pentoxil, Dimethyloxohexylxanthine, Trental, PENTOXYPHYLINE |
| Category: | Hemorrheologic Agents, Radiation-Protective Agents, Vasodilator Agents, Phosphodiesterase Inhibitors, Hematologic Agents, Free Radical Scavengers, Platelet Aggregation Inhibitors |
| CAS number: | 6493-05-6 |
Pharmacology
| Indication: | For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs. |
|---|---|
| Pharmacology: | Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
| Mechanism of Action: |
Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It...
show more » |
| Protein binding: | 70% |
| Route of elimination: | Excretion is almost totally urinary; the main biotransformation product is Metabolite V. Essentially no parent drug is found in the urine. |
| Half Life: | 0.4-0.8 hours |
| Toxicity: | LD50=1385 mg/kg(orally in mice) |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
